Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
557
datasets available to search
ShareScore release 0.9.0
Dataset results
557 results for “Imatinib”
Methylation data from biological replicates of imatinib and nilotinib resistant K-562 cells
GEO Series GSE203443. Homo sapiens. 7 samples. Type: Methylation profiling by array.
Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary KIT Mutations
GEO Series GSE247170. Homo sapiens. 9 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Genomic profiling of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients using Agilent-014698 Whole Human Genome 105K microarrays.
GEO Series GSE21986. Homo sapiens. 36 samples. Type: Genome variation profiling by genome tiling array.
Gene expression analysis of chronic myeloid leukemic stem cells and progenitor cells from untreated and imatinib-treated CML-like mice
GEO Series GSE175323. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
Identification of transcriptional difference between Imatinib-sensitive and resistant patients with gastrointerstinal stromal tumor (GIST)
GEO Series GSE155800. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing.
Lycorine attenuated proliferation and induced apoptosis on imatinib-resistant K562 cell by inhibiting autophagy.
GEO Series GSE267522. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Small RNA expression signatures of gastrointestinal stromal tumors: associations to imatinib resistance and patient outcome
GEO Series GSE45901. Homo sapiens. 17 samples. Type: Non-coding RNA profiling by array.
Gene expression signature that predicts early molecular response failure in chronic phase CML patients on frontline imatinib
GEO Series GSE130404. Homo sapiens. 96 samples. Type: Expression profiling by array.
Expression profiling in exosomal miRNAs of CML patients with musculoskeletal pain associated with discontinuation of Imatinib
GEO Series GSE85903. Homo sapiens. 13 samples. Type: Expression profiling by RT-PCR.
Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukemia cells
GEO Series GSE124894. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.
Gene expression profiling of imatinib-treated and untreated human Hematopoetic progenitors expressing the ETV6-PDGFRB oncogene
GEO Series GSE28698. Homo sapiens. 6 samples. Type: Expression profiling by array.
Comparative RNA sequencing identifies superior cytocidal mechanisms of imatinib over rapamycin in UMB1949 renal angiomyolipoma cells
GEO Series GSE193402. Homo sapiens. 15 samples. Type: Expression profiling by high throughput sequencing.
Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients
<p><strong>Background: </strong>Imatinib reduced 90-day mortality in hospitalised coronavirus disease 2019 (COVID-19) patients in a recent clinical trial, but the biological effects that cause improved clinical outcomes are unknown. We aimed to determine the biological changes elicited by imatinib in patients with COVID-19 and what baseline biological profile moderates the effect of imatinib.</p> <p><strong>Methods:</strong> We undertook a secondary analysis of a randomised, double-blind, placebo-controlled trial of oral imatinib in hospitalised, hypoxaemic COVID-19 patients. Mediating effects of changes in plasma concentration of 25 plasma host response biomarkers on the association between randomisation group and 90-day mortality were studied by combining linear mixed effect modelling and joint modelling. Moderation of baseline biomarker concentrations was evaluated by Cox regression modelling. We identified subphenotypes using Ward’s method clustering and evaluated moderation of these subphenotypes using the aforementioned method.</p> <p><strong>Results:</strong> 332 out of 385 participants had plasma samples available. Imatinib increased the concentration of surfactant protein D (SP-D), and decreased the concentration of interleukin-6, procalcitonin, angiopoietin (Ang)-2/Ang-1 ratio, E-selectin, tumour necrosis factor (TNF)-α, and TNF receptor I. The effect of imatinib on 90-day mortality was fully mediated by changes in these biomarkers. Cluster analysis revealed three host response subphenotypes. Mortality benefit of imatinib was only present in the subphenotype characterised by alveolar epithelial injury indicated by increased SP-D levels in the context of systemic inflammation and endothelial dysfunction (hazard ratio 0.30, 95% CI 0.10–0.92).</p> <p><strong>Conclusions: </strong>The effect of imatinib on mortality in hospitalised COVID-19 patients is mediated through modulation of innate immune responses and reversal of endothelial dysfunction, and possibly moderated by biological subphenotypes.</p>
Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
ClinicalTrials.gov study NCT00101088. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Positioning Imatinib for Pulmonary Arterial Hypertension
ClinicalTrials.gov study NCT04416750. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
ClinicalTrials.gov study NCT00026169. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
ClinicalTrials.gov study NCT00390156. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy
ClinicalTrials.gov study NCT02086487. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
ClinicalTrials.gov study NCT05245968. IPD Sharing: YES. Countries: 5. Publications: 0.
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
ClinicalTrials.gov study NCT00171912. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.